JP2011522835A - 抗ｃｄ８抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性ｃｄ８＋ｔ細胞の生成を導く - Google Patents

抗ｃｄ８抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性ｃｄ８＋ｔ細胞の生成を導く Download PDF

Info

Publication number
JP2011522835A
JP2011522835A JP2011512705A JP2011512705A JP2011522835A JP 2011522835 A JP2011522835 A JP 2011522835A JP 2011512705 A JP2011512705 A JP 2011512705A JP 2011512705 A JP2011512705 A JP 2011512705A JP 2011522835 A JP2011522835 A JP 2011522835A
Authority
JP
Japan
Prior art keywords
cells
antibody
suppressor
cell
peripheral blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011512705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522835A5 (https=
Inventor
ジャック エフ． バンチェレイア
イーナフ クレチェフスキー
アンナ キャロライナ パルッカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of JP2011522835A publication Critical patent/JP2011522835A/ja
Publication of JP2011522835A5 publication Critical patent/JP2011522835A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2011512705A 2008-06-06 2009-06-05 抗ｃｄ８抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性ｃｄ８＋ｔ細胞の生成を導く Pending JP2011522835A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5964708P 2008-06-06 2008-06-06
US61/059,647 2008-06-06
PCT/US2009/046464 WO2009149382A2 (en) 2008-06-06 2009-06-05 Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells

Publications (2)

Publication Number Publication Date
JP2011522835A true JP2011522835A (ja) 2011-08-04
JP2011522835A5 JP2011522835A5 (https=) 2012-07-19

Family

ID=41398905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512705A Pending JP2011522835A (ja) 2008-06-06 2009-06-05 抗ｃｄ８抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性ｃｄ８＋ｔ細胞の生成を導く

Country Status (14)

Country Link
US (1) US20090304659A1 (https=)
EP (1) EP2297204A4 (https=)
JP (1) JP2011522835A (https=)
KR (1) KR20110025812A (https=)
CN (1) CN102112491A (https=)
AU (1) AU2009255999A1 (https=)
BR (1) BRPI0915582A2 (https=)
CA (1) CA2728772A1 (https=)
IL (1) IL209798A0 (https=)
MX (1) MX2010013265A (https=)
NZ (1) NZ590197A (https=)
TW (1) TW201000130A (https=)
WO (1) WO2009149382A2 (https=)
ZA (1) ZA201100061B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013081428A (ja) * 2011-10-11 2013-05-09 Biotherapy Institute Of Japan Ｃｄ５６陽性ｔ細胞増強方法
WO2020250940A1 (ja) 2019-06-11 2020-12-17 小野薬品工業株式会社 免疫抑制剤
JP2023535708A (ja) * 2020-07-21 2023-08-21 スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド Ｃｄ８結合ポリペプチドおよびその使用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092597B2 (en) 2014-01-14 2018-10-09 The University Of Hong Kong Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice
WO2018085897A1 (en) * 2016-11-14 2018-05-17 Murdoch Childrens Research Institute Transplant rejection assay
SG11202000073XA (en) * 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
CN112156110B (zh) * 2020-09-15 2022-10-14 上海交通大学医学院 Cd8+抑制性t细胞在免疫调节中的应用及诱导方法
IL308609A (en) 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs
CN120569191A (zh) 2022-11-23 2025-08-29 乔治亚大学研究基金公司 用于增加免疫应答的组合物及其使用方法
CN120826463A (zh) * 2023-03-31 2025-10-21 杭州启函生物科技有限公司 使用工程化细胞的癌症免疫疗法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503405A (ja) * 1988-12-16 1992-06-18 クールター　エレクトロニクス　インコーポレイテッド 選択された特性を現わす集団についての細胞または形成体をスクリーニングする方法および装置
WO2004112835A2 (en) * 2003-06-20 2004-12-29 Isis Innovation Ltd Suppression of transplant rejection
JP2006500932A (ja) * 2002-09-27 2006-01-12 バイオイー， インコーポレイテッド 細胞分離組成物および細胞分離法
WO2008005859A2 (en) * 2006-06-30 2008-01-10 Baylor Research Institute Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178858A (en) * 1987-12-02 1993-01-12 Reichert Thomas A Method for prevention of graft versus host disease
US5601828A (en) * 1989-03-15 1997-02-11 Tkb Associates Limited Partnership CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
DE69132373T2 (de) * 1990-11-23 2001-03-29 Coulter Corp., Hialeah Verfahren und vorrichtung zur reihensichtung mikroskopischer zellen unter verwendung von lichtstreuenden techniken
US6911220B1 (en) * 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
ATE432339T1 (de) * 1996-04-05 2009-06-15 Univ South Alabama Verwendung von onkofötal-antigen spezifischen cd4,cd8 zytotoxischen, suppressor t-zellen und interleukin-10
IL126714A (en) * 1997-02-28 2010-12-30 Enzo Therapeutics Inc Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
US6803036B1 (en) * 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
US20040022761A1 (en) * 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
US20050042217A1 (en) * 2003-03-19 2005-02-24 Yan Qi Specific inhibition of allorejection
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503405A (ja) * 1988-12-16 1992-06-18 クールター　エレクトロニクス　インコーポレイテッド 選択された特性を現わす集団についての細胞または形成体をスクリーニングする方法および装置
JP2006500932A (ja) * 2002-09-27 2006-01-12 バイオイー， インコーポレイテッド 細胞分離組成物および細胞分離法
WO2004112835A2 (en) * 2003-06-20 2004-12-29 Isis Innovation Ltd Suppression of transplant rejection
WO2008005859A2 (en) * 2006-06-30 2008-01-10 Baylor Research Institute Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013057688; 病理と臨床 第２４巻，第５号, 2006, ｐ．４７３-４７９ *
JPN6013057690; 実験医学 第１８巻，第１５号, 2000, ｐ．２１１６-２１２２ *
JPN6013057691; Ａｍｅｒｉｃａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｔｒａｎｓｐｌａｎｔａｔｉｏｎ Ｖｏｌ．７，　Ｎｏ．５, 2007, ｐ．１０５５-１０６１ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013081428A (ja) * 2011-10-11 2013-05-09 Biotherapy Institute Of Japan Ｃｄ５６陽性ｔ細胞増強方法
WO2020250940A1 (ja) 2019-06-11 2020-12-17 小野薬品工業株式会社 免疫抑制剤
JP2023535708A (ja) * 2020-07-21 2023-08-21 スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド Ｃｄ８結合ポリペプチドおよびその使用
JP7688941B2 (ja) 2020-07-21 2025-06-05 スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド Ｃｄ８結合ポリペプチドおよびその使用

Also Published As

Publication number Publication date
KR20110025812A (ko) 2011-03-11
WO2009149382A3 (en) 2010-04-29
TW201000130A (en) 2010-01-01
EP2297204A2 (en) 2011-03-23
CN102112491A (zh) 2011-06-29
CA2728772A1 (en) 2009-12-10
AU2009255999A1 (en) 2009-12-10
NZ590197A (en) 2012-10-26
IL209798A0 (en) 2011-02-28
WO2009149382A2 (en) 2009-12-10
ZA201100061B (en) 2011-10-26
EP2297204A4 (en) 2013-10-23
MX2010013265A (es) 2011-02-24
US20090304659A1 (en) 2009-12-10
BRPI0915582A2 (pt) 2016-01-26

Similar Documents

Publication Publication Date Title
CN1981031B (zh) 调节性t细胞及它们在免疫治疗和抑制自身免疫反应中的应用
Pêche et al. Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors
JP2011522835A (ja) 抗ｃｄ８抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性ｃｄ８＋ｔ細胞の生成を導く
CA2413866C (en) Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
US9580684B2 (en) Methods and compositions for the generation and maintenance of regulatory T cells
EP3842450A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
JP2019047814A (ja) Ｂ細胞の増加及び評価方法並びに疾患治療のための増加ｂ細胞の使用方法
EP2399594B1 (en) Tumour cell-activated Natural Killer cells
US20210147800A1 (en) Methods for producing regulatory immune cells and uses thereof
US20160032245A1 (en) Compositions and Methods for Modulating an Immune Response
US20090232854A1 (en) Uses of bispecific antibody coated dendritic cells pulsed with antigens and gm-csf in immune regulation
Zhang et al. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells
US20150110738A1 (en) Methods and compositions for generating and using allogeneic suppressor cells
JP2022526856A (ja) 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法
JP2022529947A (ja) ドナーアポトーシス白血球が誘導する移植免疫寛容のバイオマーカー
Katsumata et al. Evaluation of the impact of conventional immunosuppressant on the establishment of murine transplantation tolerance–an experimental study
Naderi et al. High expression of Fas ligand on cord blood dendritic cells: a possible immunoregulatory mechanism after cord blood transplantation
HK1155467A (en) Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells
Wekerle DPPIV inhibition in a murine model of mixed chimerism and transplantation tolerance
Gur Immune regulation by early hematopoietic progenitor cells
Shiao Memory T cells and the endothelium in allograft rejection
Jaeckel et al. Human Donor-Specific Tregs Can Prevent Allograft Rejection in Humanized Immune Reconstituted Mice.: Abstract# 743
FOWLER et al. National Institutes of Health, Bethesda, Maryland, USA
HK40055433A (en) Antibody/t-cell receptor chimeric constructs and uses thereof
Bézie et al. Advances on CD8 Tregs and their potential in transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140421